Biodesix develops and commercializes blood-based diagnostics to answer unmet clinical questions across the lung cancer continuum of care.
1 in 15 people in the U.S. will be diagnosed with lung cancer in their lifetime—1 in 14 men and 1 in 17 women.
Source: SEER Cancer Statistics Review 1975-2012, Cancer of the Lung and Bronchus, Tables 15.18-15.20
Biodesix Lung Reflex®
By integrating genomic and proteomic blood-based results in 72 hours, we see both sides of lung cancer. These results can facilitate patient conversations and treatment strategies.
Product Development Pipeline
Biodesix’s rich pipeline includes the development of tests to help answer unmet clinical questions across the lung cancer continuum of care.